Heuron's imaging biomarker technology is expected not only to reduce the time and cost of developing new drugs, but also to improve the clinical success rate.
Heuron can provide the world's first Parkinson's Disease imaging biomarker. Since the development of new drugs related to cerebral neuropathy takes significant amounts of time and cost compared to other diseases, the clinical success rate has been only 8.2% due to the lack of quantitative evaluation methods and difficulty in selecting an effective patient group. However, if you proceed with the biomarker, the clinical success rate can be improved 3 times to 25.9%, lowering the cost of clinical failure.